First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032On track to share interim Phase 1b data in H1 2024Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus",
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday.
Shares of Target Corporation (NYSE: TGT) jumped during Wednesday’s session after the company reported better-than-expected third-quarter financial results.
Shares of CorMedix Inc. (NASDAQ: CRMD) surged in pre-market trading as the company posted a narrower-than-expected third-quarter loss.
Cormedix posted a loss of 17 cents per share for the third quarter, versus market expectations for a loss of 21 cents per share.